Navigating EGFR-Mutant Advanced NSCLC Cancer Treatment: A Patient's Journey
Panelists discuss Melinda's treatment journey for advanced EGFR-mutant NSCLC, including the specific treatments she received and her responses, while Dr. Spira provides a high-level overview of systemic therapies for the condition, highlighting the role of amivantamab and how management strategies are tailored based on patient and disease characteristics, with treatment decisions guided by available data.
EP: 1.Overview of EGFR-Mutant Advanced NSCLC
EP: 2.EGFR-Mutant NSCLC Diagnosis: Insights from Patients and Clinicians
EP: 3.Coordinating Care for Patients with Advanced EGFR-Mutant NSCLC: A Multidisciplinary Approach
EP: 4.Multidisciplinary Care of EGFR-Mutant Advanced NSCLC: A Patient Perspective
EP: 5.Tailoring Patient Education and Resources in EGFR-Mutant Advanced NSCLC
Now Viewing
EP: 6.Navigating EGFR-Mutant Advanced NSCLC Cancer Treatment: A Patient's Journey
Video content above is prompted by the following:
- Can you briefly walk us through your treatment journey for advanced EGFR-Mutant NSCLC?
- What specific treatments did you receive and how did you respond?
- Please provide a high-level overview of the systemic therapies that you consider for advanced EGFR-Mutant NSCLC.
- What is the role of amivantamab in treating advanced EGFR-Mutant NSCLC?
- How does your management approach differ based on patient and disease characteristics?
- How do available data guide your treatment decisions?
Recent Videos
Related Content
